Clinical trial
A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.
NCT05642429 is registered in ClinicalTrials.gov with Institute for Molecular Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients With Early Alzheimer's Disease.
- Lead sponsor
- Institute for Molecular Medicine
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- February 27, 2023
- Completion date
- November 7, 2026
- Enrollment
- 48 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.